Pricing Log in Create free account
Saturday 17 October 2026 Export JAZZ’s income statement to Excel — free account

Jazz Pharmaceuticals PLC

JAZZ Healthcare Biotechnology

Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 126.0%, free cash flow grew 141.0% and total debt fell 18.9%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

210.05 4.37 −2.04%
Market cap
$13.9B
P/E
13.8×
Fwd P/E
17.3×
Dividend yield
—
F-score
5/9
Altman Z
1.37
Beneish M
−3.03
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Jazz Pharmaceuticals PLC (JAZZ) Business Profile

Updated before January 2025

Company Overview

Jazz Pharmaceuticals PLC (JAZZ) is a global biopharmaceutical company dedicated to developing and commercializing innovative medicines that address unmet medical needs. Founded in 2003 and headquartered in Dublin, Ireland, Jazz Pharmaceuticals has grown into a leading player in the pharmaceutical industry. The company operates with a mission to improve patients’ lives by identifying, developing, and delivering life-changing therapies. Jazz Pharmaceuticals is led by a team of experienced executives, including Bruce Cozadd, the Chairman and Chief Executive Officer, who has been instrumental in driving the company’s growth and strategic direction.

Jazz Pharmaceuticals has a strong presence in the United States and Europe, with additional operations in other regions. Over the years, the company has expanded its portfolio through strategic acquisitions, partnerships, and in-house research and development efforts. Its commitment to innovation and patient care has positioned Jazz Pharmaceuticals as a trusted name in the biopharmaceutical sector.

Core Business Segments

Jazz Pharmaceuticals focuses on two primary therapeutic areas: neuroscience and oncology. These core business segments encompass a range of products and services designed to address critical medical needs.

Neuroscience

In the neuroscience segment, Jazz Pharmaceuticals specializes in treatments for sleep disorders and other central nervous system (CNS) conditions. Key products include:

  • Xyrem® (sodium oxybate): A treatment for cataplexy and excessive daytime sleepiness in patients with narcolepsy.
  • Xywav® (calcium, magnesium, potassium, and sodium oxybates): A low-sodium alternative to Xyrem, approved for narcolepsy and idiopathic hypersomnia.
  • Sunosi® (solriamfetol): A medication for improving wakefulness in adults with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.

Oncology

Jazz Pharmaceuticals has a robust oncology portfolio aimed at treating hematologic malignancies and solid tumors. Key products include:

  • Rylaze® (asparaginase erwinia chrysanthemi (recombinant)-rywn): A therapy for acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma.
  • Zepzelca® (lurbinectedin): A treatment for metastatic small cell lung cancer (SCLC).
  • Vyxeos® (daunorubicin and cytarabine liposome for injection): A therapy for adults with newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes.

Business Model

Jazz Pharmaceuticals operates a vertically integrated business model that combines research and development, manufacturing, and commercialization. The company invests heavily in R&D to discover and develop innovative therapies. It also collaborates with academic institutions, research organizations, and other pharmaceutical companies to enhance its pipeline.

Revenue generation primarily comes from product sales, with a focus on high-value, niche markets. Jazz Pharmaceuticals also leverages strategic partnerships and licensing agreements to expand its market reach and diversify its revenue streams. The company’s patient-centric approach ensures that its therapies address significant unmet medical needs, driving demand and fostering long-term growth.

Strategic Direction

Jazz Pharmaceuticals is committed to advancing its pipeline and expanding its portfolio to address critical medical needs. Key strategic priorities include:

  • Pipeline Expansion: The company is focused on developing new therapies in neuroscience and oncology, with several candidates in various stages of clinical development.
  • Geographic Expansion: Jazz aims to increase its presence in emerging markets and strengthen its foothold in existing regions.
  • Sustainability Goals: The company is dedicated to environmental sustainability and corporate social responsibility, with initiatives aimed at reducing its carbon footprint and promoting diversity and inclusion.
  • Digital Transformation: Jazz is leveraging digital technologies to enhance its R&D capabilities, streamline operations, and improve patient engagement.

Competitive Landscape

Jazz Pharmaceuticals operates in a highly competitive industry, facing competition from both large pharmaceutical companies and smaller biotech firms. Key competitors include:

  • Biogen: A leader in neuroscience therapies.
  • Amgen: Known for its oncology and hematology products.
  • Teva Pharmaceuticals: A major player in generic and specialty medicines.
  • Horizon Therapeutics: Focused on rare diseases and specialty therapies.

Despite the competition, Jazz Pharmaceuticals differentiates itself through its focus on niche markets and its commitment to innovation.

Risk Factors

Jazz Pharmaceuticals faces several risks that could impact its operations and financial performance. Key risk factors include:

  • Market Dependence: The company relies heavily on a few key products for revenue, making it vulnerable to market fluctuations and competitive pressures.
  • Regulatory Challenges: The pharmaceutical industry is highly regulated, and changes in regulatory requirements could affect product approvals and market access.
  • Supply Chain Disruptions: Global supply chain issues, including raw material shortages and manufacturing delays, could impact product availability.
  • Intellectual Property Risks: Patent expirations and challenges to intellectual property rights could affect the company’s competitive position.

Recent Developments

Jazz Pharmaceuticals has made significant strides in recent years, including:

  • New Product Launches: The introduction of Xywav for idiopathic hypersomnia and Rylaze for ALL has expanded the company’s portfolio.
  • Strategic Acquisitions: The acquisition of GW Pharmaceuticals in 2021 added Epidiolex® (cannabidiol) to its portfolio, marking its entry into the cannabinoid-based therapy market.
  • R&D Milestones: Progress in clinical trials for pipeline candidates in neuroscience and oncology.
  • Global Developments: The COVID-19 pandemic posed challenges but also highlighted the importance of resilient supply chains and digital transformation.

Investment Considerations

Investors considering Jazz Pharmaceuticals should weigh the following factors:

Strengths

  • Strong portfolio of innovative therapies.
  • Focus on niche markets with high unmet medical needs.
  • Robust pipeline and commitment to R&D.
  • Experienced leadership team and strategic vision.

Risks

  • Dependence on a few key products for revenue.
  • Regulatory and intellectual property challenges.
  • Competitive pressures in the biopharmaceutical industry.
  • Potential supply chain disruptions.

Conclusion

Jazz Pharmaceuticals PLC is a dynamic and innovative biopharmaceutical company with a strong focus on neuroscience and oncology. Its commitment to addressing unmet medical needs, coupled with a robust pipeline and strategic vision, positions it for long-term growth. While the company faces challenges, its strengths and opportunities make it a compelling player in the pharmaceutical industry. Investors should carefully consider the company’s strengths and risks when evaluating its potential as an investment opportunity.